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ABSTRACT
In this articleQ2 , the 2009 European League Against
Rheumatism (EULAR) recommendations for the
management of antineutrophil cytoplasmic antibody
(ANCA)-associated vasculitis (AAV) have been updated.
The 2009 recommendations were on the management
of primary small and medium vessel vasculitis. The 2015
update has been developed by an international task
force representing EULAR, the European Renal
Association and the European Vasculitis Society (EUVAS).
The recommendations are based upon evidence from
systematic literature reviews, as well as expert opinion
where appropriate. The evidence presented was
discussed and summarised by the experts in the course
of a consensus-ﬁnding and voting process. Levels of
evidence and grades of recommendations were derived
and levels of agreement (strengths of recommendations)
determined. In addition to the voting by the task force
members, the relevance of the recommendations was
assessed by an online voting survey among members of
EUVAS. Fifteen recommendations were developed,
covering general aspects, such as attaining remission
and the need for shared decision making between
clinicians and patients. More speciﬁc items relate to
starting immunosuppressive therapy in combination with
glucocorticoids to induce remission, followed by a period
of remission maintenance; for remission induction in life-
threatening or organ-threatening AAV, cyclophosphamide
and rituximab are considered to have similar efﬁcacy;
plasma exchange which is recommended, where
licensed, in the setting of rapidly progressive renal failure
or severe diffuse pulmonary haemorrhage. These
recommendations are intended for use by healthcare
professionals, doctors in specialist training, medical
students, pharmaceutical industries and drug regulatory
organisations.
Q1
INTRODUCTION
Granulomatosis with polyangiitis (GPA, Wegener’s
granulomatosis), microscopic polyangiitis (MPA)
and eosinophilic granulomatosis with polyangiitis
(EGPA, Churg-Strauss syndrome) are termed
the antineutrophil cytoplasmic antibody (ANCA)-
associated vasculitides (AAVs).1 GPA, MPA and
EGPA have respective annual incidence rates of
2.1–14.4, 2.4–10.1 and 0.5–3.7 per million in
Europe, and the prevalence of AAV is estimated at
to be 46–184 per million.2–8 The 5-year survival
rates for GPA, MPA and EGPA are estimated to be
74–91%, 45–76% and 60–97%, respectively.9
BACKGROUND AND RATIONALE
In 2009 the European League Against Rheumatism
(EULAR) published recommendations for managing
primary small and medium vessel vasculitis which
included the management of AAV.10 The publica-
tion of 1691 papers in the past 5 years on primary
systemic vasculitis in internal medicine, rheumatol-
ogy and nephrology journals, as well as the licens-
ing of rituximab for AAV, make this an opportune
time to update the recommendations with an AAV
focus. This update was made in conjunction with
the European Renal Association—European Dialysis
and Transplant Association (ERA-EDTA).
This paper reassesses standard therapy, including
the use of biological agents, the prognostic value
of histopathology and management of long-term
complications, integrating these into treatment
algorithms.
METHODS
The EULAR standardised operating procedure for
the elaboration, evaluation, dissemination and
implementation of recommendations were fol-
lowed.11 The full details are available in the online
supplementary material. The task force comprised
21 members representing EULAR and ERA-EDTA:
a patient ( John Mills), a nurse ( Janice Mooney), a
pathologist (IMB), an otorhinolaryngologist (ML),
a pulmonologist (BC), an immunologist (TH), an
ophthalmologist (NY), two general internists (AM,
MCC), six renal physicians (MAL, MS, VT, KW, AV
and DRJ) and six rheumatologists (RAW, BH, JUH,
RAL, PAM and CM) with academic experience
and/or clinical expertise in the ﬁeld of vasculitis.
MY was the Clinical Fellow.
A Delphi exercise was conducted to identify
items needing update and new items. This
instructed the SLR strategy. The manuscripts were
formally scored using the Critical Appraisal Skills
Programme checklist (11). Details are available in
the online supplement.
STATEMENTS
The statements in this manuscript are termed
‘recommendations’ as opposed to ‘guidelines’ or
‘points to consider’ because they offer guidance
which needs to be tailored to meet individual
requirements (table 1). They are intended for use by
healthcare professionals, doctors in specialist train-
ing, medical students, pharmaceutical industries and
drug regulatory organisations. An algorithm has
been developed to reﬂect the statements (ﬁgure 1).
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AAV is a very variable disease group which is unpredictable
and potentially life-threatening. Treatment usually involves
potent immunosuppressive drugs, often with risk of signiﬁcant
side effects. Full drug-free remission can be achieved but relapse
is common. In addition, AAV adversely affects quality of life
even in patients thought to have clinical remission.12 13 This
may be an effect of the disease or its treatment. We recommend
the overarching principle of shared decision making between
the patient and their specialist.
Statement 1
We recommend that patients with AAVare managed in close col-
laboration with, or at, centres of expertise. Level of evidence 3;
grade of recommendation C; strength of vote 100%.
The rarity of AAV makes it difﬁcult to maintain expertise in
their management.2 14–16 Assessment of these patients requires
expert guidance to differentiate activity from damage or infec-
tion and to consider differential diagnoses. Patients may require
interventions by specialists with expertise in AAV, such as
immunological monitoring, use of rituximab in patients with
refractory disease, specialised radiography, assessment of eye
involvement, injection of subglottic stenosis and renal transplant-
ation.17–24 For patients with refractory disease, the best option
may be consideration of referral to centres participating in clin-
ical trials. AAV may relapse years after remission is achieved, even
in previously unaffected organ systems.25–27 Patients may
develop complications from the treatment many years after dis-
continuing treatment.28 29 Long-term follow-up and rapid access
to specialist services are necessary for all patients with AAV. For
these reasons patients with AAV should be managed in close
collaboration with, or at, centres of expertise.30
Statement 2
A positive biopsy is strongly supportive of a diagnosis of vascu-
litis and we recommend biopsies to assist in establishing a new
diagnosis and for further evaluation for patients suspected of
having relapsing vasculitis. Level of evidence 3; grade of recom-
mendation C; strength of vote 81%.
A positive biopsy for AAV is helpful when considering an initial
diagnosis or recurrent disease. Histopathological evidence of vas-
culitis, such as pauci-immune glomerulonephritis or necrotising
vasculitis in any organ, remains the gold standard for diagnostic
purposes. The likely diagnostic yield varies and is dependent on
the organ targeted. In patients with GPA with renal involvement
the diagnostic yield from renal biopsy can be as high as 91.5%.31
Otorhinolaryngological examination in patients with GPA often
reveals abnormal ﬁndings and biopsies of these areas may be posi-
tive for inﬂammatory changes in up to 68.4%.32 33 A large study
of 60 nasal, 27 paranasal sinus, 17 laryngeal, 5 periorbital, 5 oral,
4 middle ear, 3 mastoid, 2 external ear and 3 salivary gland
Table 1 Recommendation statements
Statement Level of evidence Grade of recommendation
1. We recommend that patients with AAV are managed in close collaboration with, or at, centres of expertise. 3 C
2. A positive biopsy is strongly supportive of a diagnosis of vasculitis and we recommend biopsies to assist in
establishing a new diagnosis and for further evaluation for patients suspected of having relapsing vasculitis.
3 C
3. For remission-induction of new-onset organ-threatening or life-threatening AAV we recommend treatment with a
combination of glucocorticoids and either cyclophosphamide OR rituximab.
1 for GPA/MPA, 3 for
EGPA
A for GPA/MPA, C for EGPA
4. For remission-induction of non-organ-threatening AAV we recommend treatment with a combination of
glucocorticoids and either methotrexate or mycophenolate mofetil*.
1B B for MTX, C for MMF
5. For a major relapse of organ-threatening or life-threatening disease in AAV we recommend treatment as per new
disease with a combination of glucocorticoids and either cyclophosphamide OR rituximab.
1 for GPA/MPA, 3 for
EGPA and CYC, 4 for
EGPA and RTX
A for GPA/MPA, C for EGPA
and CYC, C for EGPA and
RTX
6. (i) Plasma exchange should be considered for patients with AAV and a serum creatine level of ≥500 mmol/L
(5.7 mg/dL) due to rapidly progressive glomerulonephritis in the setting of new or relapsing disease.
1B B
6. (ii) Plasma exchange can also be considered for the treatment of severe diffuse alveolar haemorrhage. 3 C
7. For remission-maintenance of AAV we recommend treatment with a combination of low-dose glucocorticoids and
either azathioprine, rituximab, methotrexate or mycophenolate mofetil*.
1B for GPA/MPA
3 for EGPA and AZA
A for GPA/MPA, C for EGPA
and AZA
8. We recommend that remission-maintenance therapy for AAV be continued for at least 24 months following
induction of sustained remission.
4 D
9. For patients with AAV refractory to remission-induction therapy we recommend switching from cyclophosphamide
to rituximab or from rituximab to cyclophosphamide. These patients should be managed in close conjunction
with, or referred to, an expert centre for further evaluation and potential enrolment in clinical trials.
3 C
10. We recommend that structured clinical assessment rather than ANCA testing should inform decisions on changes
in treatment for AAV.
4 D
11. We recommend the investigation of persistent unexplained haematuria in patients with prior exposure to
cyclophosphamide.
2B C
12. Hypoimmunoglobulinaemia has been noted after treatment with rituximab. We recommend testing of serum
immunoglobulin levels prior to each course of rituximab and in patients with recurrent infection.
3 C
13. We recommend periodic assessment of cardiovascular risk for patients with AAV. 2B B
14. We recommend that patients with AAV should be given a clear verbal explanation of the nature of their disease,
the treatment options, the side effects of treatment, and the short-term and long-term prognoses.
3 C
15. We recommend that following the remission-induction phase of treatment, patients with AAV be assessed for the
extent and ongoing impact of comorbidities associated with their diagnosis. Patients should then be advised
where they might find the necessary therapies or support for these conditions.
4 D
*The drugs are listed in order of the strength of vote (see text).
AAV, ANCA-associated vasculities; ANCA, antineutrophil cytoplasmic antibody; AZA, azathioprine; CYC, cyclophosphamide; EGPA, eosinophilic granulomatosis with polyangiitis; GPA,
granulomatosis with polyangiitis; MMF, mycophenolate mofetil; MPA, microscopic polyangiitis; MTX, methotrexate; RTX, rituximab.
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biopsies revealed that they often yield non-speciﬁc chronic inﬂam-
mation and the more speciﬁc ﬁndings of granulomas and vasculitis
are seen less frequently than in other tissue biopsies.34 Lung biop-
sies vary in their diagnostic sensitivity, with only 12% of trans-
bronchial biopsies of alveolar tissue positive for GPA and 66.7%
for EGPA in one study.32 Open lung biopsies, although more
invasive, provide a much higher diagnostic yield.35
Percutaneous renal biopsy should be performed using
ultrasound guidance where possible and has been shown to be
associated with a low risk of complications including haemor-
rhage.36 The risk of bleeding following percutaneous renal
biopsy is higher in patients treated with plasma exchange
(PLEX).37 Generic factors associated with an increased risk of
bleeding necessitating transfusion include old age, increased sys-
tolic blood pressure and worse renal function.38
Existing classiﬁcation systems need further validation but
changes like glomerular sclerosis have obvious adverse prognos-
tic value for patients with AAV.39–41
Statement 3
For remission-induction of new-onset organ-threatening or life-
threatening AAV we recommend treatment with a combination
of glucocorticoids and either cyclophosphamide OR rituximab.
▸ Cyclophosphamide
– level of evidence 1A for GPA and MPA; grade of recom-
mendation A; strength of vote 100%.
– level of evidence 3 for EGPA; grade of recommendation C;
strength of vote 88%.
▸ Rituximab
– level of evidence 1B for GPA and MPA; grade of recom-
mendation A; strength of vote 82%.
– level of evidence 3 for EGPA; grade of recommendation C;
strength of vote 59%.
Since the 1970s therapy consisting of a combination of gluco-
corticoids (1 mg/kg/day—maximum daily dose 80 mg) with
cyclophosphamide (2 mg/kg/day—maximum 200 mg/day) has
been used for remission induction in AAV.42 Due to concerns
about cumulative cyclophosphamide dosage, pulsed intravenous
regimens were designed and tested, the largest study being the
CYCLOPS trial.43 This trial was designed following a
meta-analysis of three studies involving 143 patients44–46 which
concluded that pulsed cyclophosphamide was more likely to
achieve remission and was associated with fewer side effects than
oral cyclophosphamide.47 Long-term follow-up of the CYCLOPS
cohort revealed that although the proportion of participants with
at least one relapse was higher in those individuals treated with
pulsed cyclophosphamide, there were no differences in survival,
renal function at the end of the study or adverse events between
the two arms.48 However, pulsed regimens are favoured due to
the reduced total dose of cyclophosphamide overall and reduced
risk of bladder-related complications.
The grade of evidence for cyclophosphamide use in EGPA is
lower than for GPA/MPA as no randomised controlled trials
(RCTs) for the treatment of EGPA have been published. One
study did compare cyclophosphamide doses: cyclophosphamide
(0.6 mg/m2) was used initially every 2 weeks for a month then
every 4 weeks.49 The intervention arm was given six pulses in
total, while the control arm received 12 pulses. Complete remis-
sion was achieved in both groups at a similar rate (21/23 in
intervention arm, 21/25 in control arm).
Antiemetic therapy should be routinely administered with
intravenous cyclophosphamide. Cyclophosphamide metabolites
are toxic to the urothelium and can cause haemorrhagic cystitis
in the short term and malignancy in the long term.28 29 50
If clinically appropriate, patients should be encouraged to
drink plenty of ﬂuids or given intravenous ﬂuids on the day of
the infusion to dilute the metabolites in the urine. Patients
receiving pulse cyclophosphamide may also be given oral or
intravenous 2-mercaptoethanesulfonate sodium (MESNA)
which binds to acrolein, a toxic metabolite of cyclophospha-
mide, rendering it non-toxic.26 MESNA also retards the degrad-
ation of 4-hydroxymetabolites, further reducing the toxic
acrolein products in the urine. MESNA may also be beneﬁcial in
patients receiving continuous oral cyclophosphamide.25 26 51
Figure 1 Algorithm to describe the management of new antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
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Monitoring of patients receiving cyclophosphamide should
follow standard protocols.52 In both modalities of administra-
tion, dose changes or discontinuation of cyclophosphamide may
be necessary in the event of an acute leucopenia or a gradual
fall over time. In the event of a stable leucopenia, it may be pos-
sible to maintain the immunosuppression with stringent blood
monitoring. We encourage prophylaxis against infection with
Pneumocystis jirovecii with trimethoprim/sulfamethoxazole
(800/160 mg on alternate days or 400/80 mg daily) in all
patients being treated with cyclophosphamide, where not con-
traindicated.53–55 The use of inhaled monthly pentamidine in
the event of an adverse reaction or contraindication to trimetho-
prim/sulfamethoxazole may be useful but is not cost-effective
and not routinely indicated.53 Other alternatives include
dapsone and atovaquone.
Rituximab in AAV has been tested in two RCTs (RAVE and
RITUXVAS).56 57 In both studies patients initially received high-
dose glucocorticoids with subsequent dose tapering. The rituxi-
mab dose in both studies was 375 mg/m2 of body surface area,
once a week for four infusions. In both trials, rituximab was
non-inferior to cyclophosphamide and appeared more effective
for relapsing disease in RAVE. Details of the clinical trials in this
section are available in the online supplement.
The grade of evidence for the use of rituximab in patients
with EGPA is lower than for GPA/MPA. A retrospective analysis
of 41 patients with EGPA who received differing regimens of
rituximab found that 34% achieved complete remission at
6 months and 49% at 12 months.58
Due to high cost, rituximab use is restricted in some countries
and therefore involvement of expert centres is mandated. There
may be speciﬁc instances where rituximab is preferable to cyclo-
phosphamide, for example, in patients who wish to preserve
their reproductive potential. Cyclophosphamide is associated
with reduced ovarian reserve, ovarian failure and male infertil-
ity.59–63 The long-term effects of rituximab on fertility have not
been studied but no such concerns have been reported. In
patients with severe disease, treatment should not be delayed
but discussion of these issues should take place.
The task force considered appropriate a target of between 7.5
mg and 10 mg of prednisolone (or equivalent) after 3 months
(12 weeks) of treatment. A review of the prednisolone protocol
reduction regimens published for the key trials illustrated that
on average a dose of 10 mg was achieved after 19 weeks, and a
dose of 7.5 mg after 21 weeks (ﬁgure 2).43 49 56 57 64–68
Therefore although a target prednisolone dose of 7.5–10mg is
desirable by 3 months, in practice it may be 5 months before
this is achieved.
The AAVs have protean manifestations and the spectrum of
disease ranges from the indolent to the life-threatening.69–73
Although the evidence and thus the recommendations follow
current classiﬁcation systems, it is not our intention to maintain
this delineation in the long term and future evidence about out-
comes of phenotypes may change current labels.
Statement 4
For remission-induction of non-organ-threatening AAV we rec-
ommend treatment with a combination of glucocorticoids and
either methotrexate or mycophenolate mofetil.
▸ Methotrexate
– Level of evidence 1B; grade of recommendation B;
strength of vote 77%.
▸ Mycophenolate mofetil
– Level of evidence 1B; grade of recommendation C;
strength of vote 65%.
The task force was keen to stress that the use of methotrexate
or mycophenolate mofetil should not be used for remission
induction in the following scenarios:
▸ Meningeal involvement
▸ Retro-orbital disease
▸ Cardiac involvement
▸ Mesenteric involvement
▸ Acute-onset mononeuritis multiplex
▸ Pulmonary haemorrhage of any severity
Methotrexate (20–25 mg/week, oral or parenteral) may be
used as an alternative to cyclophosphamide in patients with
less severe disease and in those with normal renal func-
tion.25 65 74–81 There have been trials using either methotrexate
or mycophenolate mofetil as the remission induction agent in
patients with AAV.65 Oral methotrexate 20–25 mg/week was
non-inferior to oral cyclophosphamide at 6 months but long-
term follow-up revealed that patients treated with methotrexate
had less effective disease control as compared with those treated
with cyclophosphamide.82 Methotrexate should therefore be
considered only for non-organ-threatening disease. Examples
include the following in the absence of renal involvement
▸ Nasal and paranasal disease without bony involvement
(erosion) or cartilage collapse or olfactory dysfunction or
deafness
▸ Skin involvement without ulceration
▸ Myositis (skeletal muscle only)
▸ Non-cavitating pulmonary nodules/inﬁltrate without
haemoptysis
▸ When cyclophosphamide or rituximab are not available or
contraindicated or patient choice
The induction trials involving methotrexate are generally
larger and of higher evidence grade than those using mycophe-
nolate mofetil. To date, the two RCTs using mycophenolate
mofetil have been conducted primarily in patients with MPA (of
the 76 participants 75 had MPA).83 84 MPA often affects renal
function and in such situations methotrexate would not be indi-
cated. The trials did not include patients with lung haemorrhage
or CNS involvement and therefore mycophenolate mofetil
should not be routinely preferred in life-threatening situations.
Details of the clinical trials discussed in this statement are
available in the online supplement.
Statement 5
For a major relapse of organ-threatening or life-threatening
disease in AAV we recommend treatment as per new disease
with a combination of glucocorticoids and either cyclophospha-
mide OR rituximab.
Figure 2 Protocol target prednisolone dosages in the key induction
trials of antineutrophil cytoplasmic antibody associated vasculitis.
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▸ Rituximab
– level of evidence 1B for GPA and MPA; grade of recom-
mendation A; strength of vote 94%.
– level of evidence 4 for EGPA; grade of recommendation
D; strength of vote 100%
▸ Cyclophosphamide
– level of evidence 1A for GPA and MPA; grade of recom-
mendation A; strength of vote 88%.
– level of evidence 3 for EGPA; grade of recommendation C;
strength of vote 88%.
Most trials published on remission induction in AAV make no
distinction between those participants treated for a new or
relapsing presentation of their disease. It is for these reasons
that the trial evidence for new or relapsing disease is often from
the same studies. However, some studies have distinguished
between those participants with new and relapsing disease and
have stratiﬁed by this factor when randomising patients.
The largest RCT to investigate the use of rituximab for remis-
sion induction in AAV (RAVE) stratiﬁed participants by new or
relapsing disease: those with relapsing disease treated with ritux-
imab were more likely to be in disease remission at the 6-month
and 12 month time points but not the 18 month follow-up
visit.57
The cumulative dose of cyclophosphamide is related to tox-
icity and is a particular concern with prolonged oral dosing,
where cumulative doses are higher.85 For this reason the task
force has favoured a greater strength of recommendation for
rituximab over cyclophosphamide for relapsing disease.
The treatment of non-severe relapses in AAV with a tempor-
ary increase in the glucocorticoid dose restores disease remission
in most patients but recurrent relapses within a relatively short
time period remain common.86 Given these data, alternative
approaches to the treatment of non-severe relapses must be con-
sidered, especially if relapses are frequent. We therefore recom-
mend treatment with intensiﬁcation or modiﬁcation of the
immunosuppressive remission maintenance regimen. The details
of the data are available in the online supplement.
Statement 6
Plasma exchange should be considered for patients with AAV
and a serum creatine level of >500 mmol/L (5.7 mg/dL) due to
rapidly progressive glomerulonephritis in the setting of new or
relapsing disease. Level of evidence 1B; grade of recommenda-
tion B; strength of vote 77%.
Plasma exchange can also be considered for the treatment of
severe diffuse alveolar haemorrhage. Level of evidence 3; grade
of recommendation C; strength of vote 88%.
PLEX use is usually reserved for patients with either
severe renal impairment or those with diffuse alveolar haemor-
rhage.87–89 The largest trial published to date is MEPEX which
recruited those individuals with either a serum creatine
>500 mmol/L (5.7 mg/dL) or those requiring dialysis.68
Long-term follow-up and analysis of this trial have also been
published.90 PLEX appeared to be of value in preventing end-
stage renal disease or death at 3 months,68 but long-term
follow-up revealed no statistically signiﬁcant beneﬁt for the
PLEX group.91 A prior meta-analysis had concluded that PLEX
may decrease the composite end point of ESRD or death in
patients with renal vasculitis.92
However most trials of PLEX did not restrict use to indivi-
duals with a serum creatine >500 mmol/L (5.7 mg/dL). One
RCT with long-term follow-up tested whether PLEX may
beneﬁt individuals with a serum creatine of <500 mmol/L
(5.7 mg/dL):93 after 1 month, none of the PLEX participants
required haemodialysis (HD) or had worsening renal function
compared with six with declining renal function and ﬁve on
HD in the reference group (p<0.05).93 Despite the improve-
ments in renal function, there were no differences in all-cause
mortality between the PLEX and reference groups after 5 years
of follow-up.93 PEXIVAS is a global trial that is currently
recruiting patients with moderate renal impairment
(eGFR<50 mL/min) and aims to provide deﬁnitive answers
regarding the use of PLEX in AAV.90
Further details about the clinical trials and the PEXIVAS
protocol are available in the online supplement.
There is also potential beneﬁt for PLEX in patients with AAV
who are also anti-GBM antibody positive, particularly those in
whom there is linear staining of IgG on the glomerular base-
ment membrane, and PLEX should be performed early in such
patients to improve outcome.89 94
Statement 7
For remission maintenance of AAV we recommend treatment
with a combination of low-dose glucocorticoids and either
azathioprine, rituximab, methotrexate or mycophenolate
mofetil.
GPA/MPA
▸ Azathioprine
– Level of evidence 1B for GPA and MPA; grade of recom-
mendation A; strength of vote 94%.
▸ Rituximab
– Level of evidence 1B for GPA and MPA; grade of recom-
mendation A; strength of vote 59%.
▸ Methotrexate
– Level of evidence 1B for GPA and MPA; grade of recom-
mendation A; strength of vote 53%
▸ Mycophenolate mofetil
– Level of evidence 1B for GPA and MPA; grade of recom-
mendation A; strength of vote 53%
EGPA
▸ Azathioprine
– Level of evidence 3 for EGPA; grade of recommendation
C; strength of vote 77%.
Long-term therapy with cyclophosphamide has been used to
maintain remission in patients with AAV.25 However the toxicity
of long-term cyclophosphamide makes it an unattractive
option.28 50 29 Azathioprine (2 mg/kg/day) is safer than oral
cyclophosphamide but as effective at 18 months in preventing
relapse.67 95 Methotrexate (20–25 mg/kg/week) has been effect-
ively used for maintenance therapy after induction of remission
with cyclophosphamide (if the serum creatine is <130 mmol/L
or 1.5 mg/dL).96 97 Leﬂunomide (20–30 mg/day) may be more
effective than methotrexate in remission maintenance but is
associated with more adverse effects.98 Therefore leﬂunomide is
considered for second line treatment in cases of intolerance to
azathioprine, methotrexate, mycophenolate mofetil or rituxi-
mab. Early cessation of therapy is associated with an increased
risk of relapse.65
The MAINRITSAN trial compared low-dose rituximab in
GPA/MPA (at a ﬁxed 500 mg dose) to tapering dose of
azathioprine for remission maintenance after induction with
pulsed cyclophosphamide.99 At month 28, major relapses had
occurred: 17 in the azathioprine group and 3 in the rituximab
group. Renal relapses occurred in 8/17 major relapses in the
azathioprine group and 0/3 in the rituximab group.99
Azathioprine is preferred over mycophenolate mofetil for
remission maintenance, because of the results from the
IMPROVE trial.100 In both groups the remission maintenance
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agent was reduced at two time points (after 12 months and
18 months) and withdrawn after 42 months.100 Relapses were
noted in 42 participants treated with mycophenolate mofetil
and in 30 participants in the azathioprine group (p<0.01).
The addition of trimethoprim/sulfamethoxazole (800/160 mg
twice daily) to standard remission maintenance can reduce the
risk of relapse in GPA.101 Although trimethoprim/sulfamethoxa-
zole has been used as the sole remission maintenance agent in
half the patients of one RCT, trimethoprim/sulfamethoxazole
monotherapy may not be effective for maintenance of remis-
sion.101 102 In patients with nasal disease, treatment with topical
antibiotics such as mupirocin may be considered in the presence
of chronic carriage of nasal Staphylococcus aureus.103
Statement 8
We recommend that remission-maintenance therapy for AAV be
continued for at least 24 months following induction of sus-
tained remission. Level of evidence 4; grade of recommendation
D; strength of vote 75% for MPO persistent disease, 62% for
MPO negative disease, 100% for PR3 persistent disease and
92% for PR3 negative disease.
No published RCTs have directly compared duration of main-
tenance therapy regimens. Early cessation of therapy is asso-
ciated with an increased risk of relapse.65 104 Most of the data
regarding relapse risk are derived from a combination of obser-
vational cohort data and long-term follow-up from clinical
trials. There are however important differences in the make-up
of the participants from these sources, with many more patients
with GPA likely to be present in observational cohort studies.105
In general, attempts at reduction of glucocorticoids should
be made prior to tapering of the immunosuppressive agent.
A meta-analysis of 13 studies (8 RCTs and 5 observational
studies with 983 participants) examining the effect of duration
of glucocorticoids on relapse rate concluded that continuing glu-
cocorticoids is associated with fewer relapses.106 The pooled
total estimate for the proportion of patients suffering with a
relapse recruited to RCTs was 36% (95% CI 25% to 47%) but
only 14% for those studies which continued glucocorticoids. In
patients with AAV with renal involvement, worse prognosis is
associated with those who have MPO-ANCA, even after adjust-
ment for baseline factors such as age, sex and serum creatine.107
Furthermore, patients with MPO-ANCA have more severe tubu-
lointerstitial inﬂammation and both CD3(+) T cell tubulitis and
tubular atrophy are independently associated with eGFR at 12
months.108 In addition, kidney biopsies displaying sclerosis are
associated with worse outcomes in AAV.109 However patients
with PR3-ANCA and those with cardiovascular or lung involve-
ment are more likely to relapse.72 110 The resultant grade for
the strength of recommendation of the task force reﬂects the
lack of data for this area. It should be noted that there was a
trend to increase the duration of therapy in patients who are
PR3-ANCA positive and this was reﬂected with median of the
vote for 36 months of maintenance therapy in this particular
scenario.
Statement 9
For patients with AAV refractory to remission-induction therapy
we recommend switching from cyclophosphamide to rituximab
or from rituximab to cyclophosphamide. These patients should
be managed in close conjunction with, or referred to, an expert
centre for further evaluation and potential enrolment in clinical
trials. Level of evidence 3; grade of recommendation C;
strength of vote 71%.
Refractory disease is deﬁned by EULAR as:111
▸ Unchanged or increased disease activity in acute AAV after
4 weeks of treatment with standard therapy in acute AAV, or
▸ Lack of response, deﬁned as <50% reduction in the disease
activity score (eg, Birmingham Vasculitis Activity Score
(BVAS) or BVAS/WG), after 6 weeks of treatment, or
▸ Chronic, persistent disease deﬁned as presence of at least one
major or three minor items on the disease activity score after
>12 weeks of treatment.
It is important to consider why a particular patient may have
refractory disease and what is driving the conclusion that they
have refractory disease. Items to consider are:
▸ Re-evaluate the primary diagnosis; are they truly refractory—
do they have AAV?
▸ Has the treatment regimen been optimised, that is, have
target dosages for therapy been reached?
▸ Is this active disease or could it be damage?
▸ Is the present disease due to AAV or could it be due to an
infection or other comorbidity or possible malignancy?
Rituximab has proven useful in patients with refractory
disease, particularly those previously treated with cyclophospha-
mide. Patients with refractory renal disease have the greatest
chance of improvement, while those with retro-orbital disease
pose a particular challenge.58 73 112 113 Based on the results of
an additional analysis of the WEGENT trial, as a potential strat-
egy the task force suggested a switch from pulsed to oral cyclo-
phosphamide when rituximab is unavailable, under the
guidance of an expert centre.114
In the follow-up of patients enrolled into the RAVE trial who
failed to achieve the primary end point, treatment with blinded
cross-over or according to best medical judgement by the trial
physician lead to disease control in the majority.115 Rituximab
may be better than cyclophosphamide for those participants
who are PR3-ANCA positive.115
For patients who fail to achieve remission and have persistent
low activity, adjunctive therapy with intravenous immunoglobu-
lin (IVIG) may help patients achieve remission.116–118 Prior to
therapy, serum immunoglobulin levels must be measured
because patients with selective IgA deﬁciency may develop an
anaphylactic reaction on receiving IVIG or a pre-existing hyper-
globulinaemia may become aggravated leading to a hyperviscos-
ity state.
Further details of the data discussed in this statement are
available in the online supplement.
Statement 10
We recommend that structured clinical assessment rather than
ANCA testing should inform decisions on changes in treatment
for AAV. Level of evidence 4; grade of recommendation D;
strength of vote 100%.
The role of ANCA testing as a means of predicting future
relapse is controversial and evolving.119–122 ANCA testing
should be performed at accredited labs which take part in
quality assurance testing programmes.123 124 A negative ANCA
does not rule out AAV in the appropriate clinical context of
active disease.125 126
Some studies have shown that patients in whom the ANCA
titres either persist, rise fourfold or become positive have a
higher incidence of relapse, while other studies did not conﬁrm
this association.95 121 120 We believe that these factors should
not lead to a change in therapy but more frequent clinical
assessment should be considered.
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Multiorgan involvement is common in AAV therefore a struc-
tured clinical assessment should be conducted in all patients.
This examination may be facilitated by the use of clinical tools
such as BVAS and the Vasculitis Damage Index.127–130 BVAS
(V.3) was modiﬁed in 2008.127 Other validated tools include
BVAS/WG, the Disease Extent Index and the Five Factor
Score.131 132 These tools have a high degree of correlation and
are reliable.133 Training and certiﬁcation in using these tools is
recommended for clinicians caring for patients with AAV.
A structured examination of the patient should be carried out
at each clinic visit to detect new organ involvement, which may
develop at any time in the disease course.134 Urinalysis should
be performed on each patient at each visit to screen for infec-
tion, renal relapse or response, as well as bladder complica-
tions.28 50 29 During follow-up, inﬂammatory markers and renal
function should be measured periodically (every 1–3 months) to
monitor disease status. A full blood count and liver function
should be performed at similar intervals to screen for drug tox-
icity.52 67 An acute fall in white cell count or a progressive
leucopenia may require reduction or discontinuation of
immunosuppressive drugs. Similarly, declining renal function
may necessitate dose adjustment or alteration of immunosup-
pressive agents. Patients should have periodic assessment of
their blood glucose while on glucocorticoid therapy.10
Statement 11
We recommend the investigation of persistent unexplained
haematuria in patients with prior exposure to cyclophospha-
mide. Level of evidence 2B; grade of recommendation C;
strength of vote 100%.
The use of cyclophosphamide is strongly associated with the
risk of bladder cancer.28 29 50 The use of MESNA as an uropro-
tective agent lowers the risk of haemorrhagic cystitis but there is
no clear evidence that it protects against bladder cancer.85
Transitional cell cancer can occur within months of commence-
ment of cyclophosphamide or many years after its discontinu-
ation.28 Tobacco smokers are particularly susceptible and may
develop the cancer at lower doses and earlier than non-
smokers.28 All patients should have periodic urinalysis for the
duration of their follow-up. In the presence of haematuria con-
ﬁrmed on urine microscopy, an urgent urology opinion must be
sought.
Statement 12
Hypoimmunoglobulinaemia has been noted after treatment
with rituximab. We recommend testing of serum immunoglobu-
lin levels prior to each course of rituximab and in patients with
recurrent infection. Level of evidence 3; grade of recommenda-
tion C; strength of vote 65%.
Hypoimmunoglobulinaemia is associated with repeated use of
cyclophosphamide and rituximab and is dependent on the
cumulative dose of the drugs used. Cyclophosphamide treat-
ment results in a decrease in immunoglobulin (Ig) levels and
subsequent rituximab treatment in patients resulted in a further
decline in Ig levels.24 Surveying patients with AAV is warranted
post cyclophosphamide and rituximab treatment for serum
immunoglobulin concentrations and persisting hypoimmunoglo-
bulinaemia.24 In patients who develop this complication,
involvement of a clinical immunologist is recommended. Not all
patients who develop hypoimmunoglobulinaemia have infec-
tious complications.135
Patients with AAV should be immunised against infectious
disease according to local policy. It should be noted that inﬂu-
enza vaccination does not appear to be associated with relapse
in patients with AAV.136 137 In addition patients with GPA show
an adequate immune response to inﬂuenza vaccination.138
Vaccination against herpes zoster (follow local guidelines
because this is a live vaccine which may be contraindicated in
immunosuppressed patients), pneumococcus and inﬂuenza
should be considered in patients with AAV. However one should
take into account the patients’ need for treatment of their AAV
and of likely treatment choice for both induction and mainten-
ance therapy. Live attenuated vaccines should be avoided when-
ever possible. We refer readers to the EULAR recommendation
for vaccination in adult patients with autoimmune inﬂammatory
rheumatic diseases.139
Further discussion is available in the online supplement.
Statement 13
We recommend periodic assessment of cardiovascular risk for
patients with AAV. Level of evidence 2B; grade of recommenda-
tion B; strength of vote 53%.
Patients with AAVare at risk of complications, both from their
disease and its treatment.134 In AAV, renal, otolaryngological
and treatment-related complications (cardiovascular disease, dia-
betes, osteoporosis and malignancy) and damage increase over
time. Around a third of patients have ≥ﬁve items of damage at a
mean of 7 years post diagnosis. At long-term follow-up, the
most commonly reported items of treatment-related complica-
tions or damage were hypertension (41.5%; 95% CI 35.6% to
47.4%), osteoporosis (14.1%; 9.9% to 18.2%), malignancy
(12.6%; 8.6% to 16.6%) and diabetes (10.4%; 6.7% to
14.0%). Given that hypertension and diabetes are well known
cardiovascular risk factors it is perhaps unsurprising that
patients with AAV are at an increased risk for cardiovascular
disease. However, the risk of cardiovascular disease appears to
be greater than can be explained through traditional cardiovas-
cular risk factors alone. A comparison of 535 participants with
5-year follow-up from four European Vasculitis Society (EUVAS)
trials revealed that within 5 years of diagnosis, 14% of patients
with GPA or MPA will have a cardiovascular event.140 This
study also showed that independent determinants of cardiovas-
cular outcome were: older age (OR 1.45, 95% CI 1.11 to 1.90),
diastolic hypertension (OR 1.97, 95% CI 0.98 to 3.95) and
PR3-ANCA (OR 0.39, 95% CI 0.20 to 0.74).140 Annual review
of traditional Framingham risk factors is appropriate.
Patients with AAV are at risk of long-term kidney damage.
Guidelines exist on the management of CKD such as KDIGO
(http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/
KDIGO_2012_CKD_GL.pdf ).
Statement 14
We recommend that patients with AAV should be given a clear
verbal explanation of the nature of their disease, the treatment
options, the side effects of treatment, and the short-term and
long-term prognoses. Level of evidence 3; grade of recommen-
dation C; strength of vote 88%.
It is a generally accepted principle in medical practice that
patients who are well informed and educated about their illness
and understand it have better outcomes. An evaluation of
patient education has taken place using an inpatient education
programme in a tertiary referral centre, although this was not a
RCT.141 Patients should be encouraged to share responsibility
for dealing with their illness.141
AAV can be a bewildering and confusing illness for patients
who can be very fearful when receiving a diagnosis of such an
uncommon disease. Like all rare diseases there is little common
experience and understanding of vasculitis so there are no
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readily available sources of information. Patients with rare dis-
eases often feel isolated and alone.142
The internet can now provide access to reliable and
up-to-date information and advice, and to patient support
groups which provide the reassurance of peer support and the
ability to share knowledge and experience. The internet can
also provide incorrect, unproven and even dangerous informa-
tion. It is often the least articulate and least conﬁdent who are
most vulnerable and need support.
AAV is characteristically a relapsing disease. Each relapse may
result in further morbidity so early prediction or recognition of
relapse is essential. A patient who understands and is educated
about the disease is frequently better able to recognise the early
signs and symptoms of relapse.
Statement 15
We recommend that following the remission-induction phase of
treatment, patients with AAV be assessed for the extent and
ongoing impact of comorbidities associated with their diagnosis.
Patients should then be advised where they might ﬁnd the
necessary therapies or support for these conditions. Level of evi-
dence 4; grade of recommendation D; strength of vote 100%.
AAV is a systemic disease with the potential to affect almost
any organ.143 Patients may be left with permanent damage to
kidneys, lungs and respiratory tract, heart, peripheral and
central nervous system, total or partial loss of sight or
hearing.144 145 Patients may lose digits or limbs or be left with
facial disﬁgurement (like a saddle-nose) or severe skin scar-
ring.27 Severe fatigue, muscle weakness and chronic pain are fre-
quent direct consequences of AAV.146 147 Side effects of
treatment can be serious, even life-threatening.148
The consequences of AAV may have a serious impact on edu-
cation, employment prospects and job retention.149 Personal
and social relationships may be seriously disrupted, sometimes
resulting in the total breakdown of family bonds. These factors
may contribute to depression as a secondary consequence of
AAV.150 151
AAV is a controllable but currently incurable lifelong illness.
Treating clinicians need to be aware that AAV often has long-
term lifestyle consequences. A ‘holistic’ approach to treatment
and ongoing care should be adopted.
DISCUSSION
Implementation of these recommendations
The recommendations have been based on an extensive litera-
ture search. In the absence of evidence, statements have been
based on the opinion and practice of experts from 12 countries
(Czech Republic, France, Germany, Ireland, Italy, Netherlands,
Spain, Sweden, Switzerland, Turkey, UK and USA). The applica-
tion of internationally accepted grading criteria prevents us
from supporting some of the statements with stronger grades.
The project has also led the committee to propose a research
agenda for AAV (see box 1). These recommendations have been
multidisciplinary with inputs from rheumatologists, internists,
renal physicians and also from a clinical immunologist, an oto-
rhinolaryngologist, a chest physician, an ophthalmologist, a vas-
culitis nurse and a patient with vasculitis. In addition to these
recommendations, we have also produced advice on AAV involv-
ing the eye and the nose (online supplement) and a lay summary
for patients and relatives (online supplement).
The previous recommendations were published in 2009 and
importantly had a wider remit, covering small and medium
vessel vasculitis and not just AAV.10 Readers are encouraged to
refer to them for treatment decisions on: mixed essential
cryoglobulinaemic vasculitis (non-viral), the use of antiviral
therapy for the treatment of hepatitis C associated cryoglobuli-
naemic vasculitis and antiviral therapy, PLEX and glucocorti-
coids for hepatitis B-associated PAN Q3. Ultimately the treatment
aim of viral-associated cryoglobulinaemic vasculitis should be to
treat the underlying viral disease according to current best man-
agement strategies.
The current recommendations provide a framework of prac-
tice which have updated the previous recommendations and
should apply to the majority of patients with AAV. Although
once again 15 statements have been formulated; some have
been changed and some have been combined: for example there
is no longer a separation of glucocorticoids as they are used in
conjunction with other immunosuppressive agents. For remis-
sion maintenance the voting of the task force reveals that
azathioprine is the preferred option over other immunosuppres-
sive agents. In speciﬁc situations, where a less aggressive induc-
tion regimen has to be preferred—methotrexate or
mycophenolate mofetil may be recommended. The task force
appreciates that the induction trials involving methotrexate are
larger and of higher evidence grade than those using mycophe-
nolate mofetil. We have been explicit in the limited scenarios
where methotrexate or mycophenolate mofetil may be justiﬁed.
Each statement should be an opportunity for auditing clinical
practice (an audit tool has been produced—see online supple-
ment). In addition these current recommendations have pro-
duced algorithms which provide clear and concise information
for the management of AAV (see ﬁgure 1).
These recommendations have also been voted on by the
EUVAS membership the results of which are available as a sup-
plementary online ﬁle (see online supplement). The results of
the EUVAS vote are largely in agreement with the strength of
recommendation vote by the task force. There are differences
particularly when there are a number of options available and
the resultant vote may represent the diversity of the EUVAS
membership. Importantly task force members who are also
members of EUVAS did not vote in the EUVAS survey.
Recommendations for clinical management need periodic updat-
ing and because of the many advances and ongoing research in
this ﬁeld, this group recommends an update of these recommen-
dations should be conducted in 3 years.
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Box 1 Research agenda
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